利妥昔-话题@MedSci

#利妥昔#

179篇内容 | 3543人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1660438, encodeId=86fe1660438a0, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Pharmacotherapy：利妥昔单抗vs 糖皮质激素治疗Graves眼眶病效果如何？, objectType=article, longId=141680, objectId=7f1914168040, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f1914168040, replyNumber=0, likeNumber=58, createdTime=2018-12-30, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f1914168040, moduleTitle=Pharmacotherapy：利妥昔单抗vs 糖皮质激素治疗Graves眼眶病效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f1914168040)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660435, encodeId=c1171660435ed, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=PLOS ONE：利妥昔单抗治疗多发性硬化症的临床有效性和安全性, objectType=article, longId=138271, objectId=2c071382e163, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c071382e163, replyNumber=0, likeNumber=75, createdTime=2019-04-18, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c071382e163, moduleTitle=PLOS ONE：利妥昔单抗治疗多发性硬化症的临床有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c071382e163)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660417, encodeId=3df8166041e75, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=NEJM：套细胞淋巴瘤患者自体干细胞移植后使用利妥昔单抗维持治疗可延长反应时间, objectType=article, longId=114848, objectId=852411484844, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=852411484844, replyNumber=0, likeNumber=73, createdTime=2018-05-13, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=852411484844, moduleTitle=NEJM：套细胞淋巴瘤患者自体干细胞移植后使用利妥昔单抗维持治疗可延长反应时间, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=852411484844)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660423, encodeId=29f51660423dd, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=【ASH 2017】利妥昔单抗时代首次缓解后自体造血干细胞移植巩固治疗可以提高年轻套细胞淋巴瘤患者总生存, objectType=article, longId=121505, objectId=d3211215052f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3211215052f, replyNumber=0, likeNumber=70, createdTime=2018-07-25, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3211215052f, moduleTitle=【ASH 2017】利妥昔单抗时代首次缓解后自体造血干细胞移植巩固治疗可以提高年轻套细胞淋巴瘤患者总生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3211215052f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660410, encodeId=95501660410c4, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Arthritis Rheumatol：自身免疫或炎性全身疾病中利妥昔单抗引起的HHV-8肿瘤, objectType=article, longId=106263, objectId=3d6e10626343, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d6e10626343, replyNumber=0, likeNumber=76, createdTime=2018-02-19, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d6e10626343, moduleTitle=Arthritis Rheumatol：自身免疫或炎性全身疾病中利妥昔单抗引起的HHV-8肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d6e10626343)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660406, encodeId=bfec1660406bd, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Arthritis Rheumatol：利妥昔单抗治疗原发性干燥综合征疲劳和口干的成本效益分析, objectType=article, longId=104131, objectId=0ebe1041310a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ebe1041310a, replyNumber=0, likeNumber=57, createdTime=2017-12-06, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ebe1041310a, moduleTitle=Arthritis Rheumatol：利妥昔单抗治疗原发性干燥综合征疲劳和口干的成本效益分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ebe1041310a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660415, encodeId=fab3166041532, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Blood：利妥昔单抗为基础的一线疗法对allo-SCT后cGVHD的效果。, objectType=article, longId=111729, objectId=7a14111e299d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a14111e299d, replyNumber=0, likeNumber=58, createdTime=2018-08-16, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a14111e299d, moduleTitle=Blood：利妥昔单抗为基础的一线疗法对allo-SCT后cGVHD的效果。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a14111e299d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660401, encodeId=76a816604018b, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=CLIN CANCER RES：依鲁替尼联合利妥昔单抗治疗高风险慢性淋巴细胞性白血病, objectType=article, longId=97949, objectId=75999e94942, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75999e94942, replyNumber=0, likeNumber=80, createdTime=2017-10-19, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75999e94942, moduleTitle=CLIN CANCER RES：依鲁替尼联合利妥昔单抗治疗高风险慢性淋巴细胞性白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75999e94942)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660409, encodeId=a0591660409e6, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Br J Haematol：利妥昔单抗二线治疗儿童AIHA的获益及风险, objectType=article, longId=105909, objectId=dff410590995, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dff410590995, replyNumber=0, likeNumber=71, createdTime=2017-07-25, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dff410590995, moduleTitle=Br J Haematol：利妥昔单抗二线治疗儿童AIHA的获益及风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dff410590995)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660405, encodeId=72981660405b6, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Ann Rheum Dis：治疗活动性类风湿关节炎GP2013和利妥昔单抗联合MTX具有生物等效性, objectType=article, longId=103145, objectId=ed31103145f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed31103145f9, replyNumber=0, likeNumber=66, createdTime=2018-04-13, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed31103145f9, moduleTitle=Ann Rheum Dis：治疗活动性类风湿关节炎GP2013和利妥昔单抗联合MTX具有生物等效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed31103145f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660416, encodeId=0bd2166041652, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=J Am Acad Dermatol：利妥昔单抗治疗的天疱疮患者，复发的生物标志物有哪些？, objectType=article, longId=114562, objectId=fe7d114562f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe7d114562f9, replyNumber=0, likeNumber=56, createdTime=2018-01-08, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe7d114562f9, moduleTitle=J Am Acad Dermatol：利妥昔单抗治疗的天疱疮患者，复发的生物标志物有哪些？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe7d114562f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660404, encodeId=42e816604048d, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Am J Hematol：BCL2突变是否导致利妥昔单抗治疗的滤泡性淋巴瘤患者预后不良？, objectType=article, longId=100766, objectId=a2e7100e6654, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2e7100e6654, replyNumber=0, likeNumber=72, createdTime=2017-10-19, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2e7100e6654, moduleTitle=Am J Hematol：BCL2突变是否导致利妥昔单抗治疗的滤泡性淋巴瘤患者预后不良？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2e7100e6654)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660424, encodeId=b0d2166042431, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=【2017 ASH】伊布替尼联合利妥昔单抗用于慢性淋巴细胞白血病, objectType=article, longId=122418, objectId=f1f41224182c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1f41224182c, replyNumber=0, likeNumber=33, createdTime=2018-04-05, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1f41224182c, moduleTitle=【2017 ASH】伊布替尼联合利妥昔单抗用于慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1f41224182c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660407, encodeId=d1ef166040eff, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Ann Rheum Dis：系统性红斑狼疮中使用B细胞生物标记物预测和管理利妥昔单抗无应答, objectType=article, longId=104914, objectId=fd371049147b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd371049147b, replyNumber=0, likeNumber=98, createdTime=2017-07-28, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd371049147b, moduleTitle=Ann Rheum Dis：系统性红斑狼疮中使用B细胞生物标记物预测和管理利妥昔单抗无应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd371049147b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660414, encodeId=cb8d1660414ef, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Rheumatology：利妥昔单抗对RA相关的间质性肺疾病的进展有何影响？, objectType=article, longId=111306, objectId=ac4d1113068e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac4d1113068e, replyNumber=0, likeNumber=95, createdTime=2017-09-20, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac4d1113068e, moduleTitle=Rheumatology：利妥昔单抗对RA相关的间质性肺疾病的进展有何影响？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac4d1113068e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660399, encodeId=c8f5166039971, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lancet：利妥昔单抗联合短期的泼尼松疗法治疗天疱疮, objectType=article, longId=93292, objectId=a9849329210, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9849329210, replyNumber=0, likeNumber=63, createdTime=2017-09-13, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9849329210, moduleTitle=Lancet：利妥昔单抗联合短期的泼尼松疗法治疗天疱疮, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9849329210)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660398, encodeId=5807166039883, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Blood:一项LYSA研究：利妥昔单抗暴露受基线代谢肿瘤体积影响并可预测DLBCL患者疗效, objectType=article, longId=90981, objectId=fe4c90981ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe4c90981ab, replyNumber=0, likeNumber=0, createdTime=2017-10-12, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe4c90981ab, moduleTitle=Blood:一项LYSA研究：利妥昔单抗暴露受基线代谢肿瘤体积影响并可预测DLBCL患者疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe4c90981ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660408, encodeId=ae5a1660408e0, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lancet Haematol：利妥昔单抗一线治疗滤泡性淋巴瘤：皮下vs静脉, objectType=article, longId=105799, objectId=110d105e99fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=110d105e99fc, replyNumber=0, likeNumber=64, createdTime=2017-08-15, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=110d105e99fc, moduleTitle=Lancet Haematol：利妥昔单抗一线治疗滤泡性淋巴瘤：皮下vs静脉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=110d105e99fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660412, encodeId=d2d9166041234, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Arthritis Rheumatol：利妥昔单抗治疗原发性干燥综合征患者疲乏和口干令人失望, objectType=article, longId=107436, objectId=76ec10e436b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76ec10e436b1, replyNumber=0, likeNumber=121, createdTime=2018-07-11, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76ec10e436b1, moduleTitle=Arthritis Rheumatol：利妥昔单抗治疗原发性干燥综合征患者疲乏和口干令人失望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76ec10e436b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660397, encodeId=7f2d166039e1f, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=JAMA Dermat：利妥昔单抗治疗顽固性疱疹样皮炎, objectType=article, longId=87972, objectId=e1f48e97210, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1f48e97210, replyNumber=0, likeNumber=95, createdTime=2017-02-06, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1f48e97210, moduleTitle=JAMA Dermat：利妥昔单抗治疗顽固性疱疹样皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1f48e97210)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

利妥昔

2020-05-29

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Pharmacotherapy：利妥昔单抗vs 糖皮质激素治疗Graves眼眶病效果如何？

2018-12-30

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

PLOS ONE：利妥昔单抗治疗多发性硬化症的临床有效性和安全性

2019-04-18

heli0118 (审核中...)

前往app查看评论内容

#利妥昔#

NEJM：套细胞淋巴瘤患者自体干细胞移植后使用利妥昔单抗维持治疗可延长反应时间

2018-05-13

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

【ASH 2017】利妥昔单抗时代首次缓解后自体造血干细胞移植巩固治疗可以提高年轻套细胞淋巴瘤患者总生存

2018-07-25

heli0118 (审核中...)

前往app查看评论内容

#利妥昔#

Arthritis Rheumatol：自身免疫或炎性全身疾病中利妥昔单抗引起的HHV-8肿瘤

2018-02-19

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Arthritis Rheumatol：利妥昔单抗治疗原发性干燥综合征疲劳和口干的成本效益分析

2017-12-06

heli0118 (审核中...)

前往app查看评论内容

#利妥昔#

Blood：利妥昔单抗为基础的一线疗法对allo-SCT后cGVHD的效果。

2018-08-16

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

CLIN CANCER RES：依鲁替尼联合利妥昔单抗治疗高风险慢性淋巴细胞性白血病

2017-10-19

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Br J Haematol：利妥昔单抗二线治疗儿童AIHA的获益及风险

2017-07-25

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Ann Rheum Dis：治疗活动性类风湿关节炎GP2013和利妥昔单抗联合MTX具有生物等效性

2018-04-13

heli0118 (审核中...)

前往app查看评论内容

#利妥昔#

J Am Acad Dermatol：利妥昔单抗治疗的天疱疮患者，复发的生物标志物有哪些？

2018-01-08

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Am J Hematol：BCL2突变是否导致利妥昔单抗治疗的滤泡性淋巴瘤患者预后不良？

2017-10-19

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

【2017 ASH】伊布替尼联合利妥昔单抗用于慢性淋巴细胞白血病

2018-04-05

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Ann Rheum Dis：系统性红斑狼疮中使用B细胞生物标记物预测和管理利妥昔单抗无应答

2017-07-28

heli0118 (审核中...)

前往app查看评论内容

#利妥昔#

Rheumatology：利妥昔单抗对RA相关的间质性肺疾病的进展有何影响？

2017-09-20

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lancet：利妥昔单抗联合短期的泼尼松疗法治疗天疱疮

2017-09-13

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Blood:一项LYSA研究：利妥昔单抗暴露受基线代谢肿瘤体积影响并可预测DLBCL患者疗效

2017-10-12

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lancet Haematol：利妥昔单抗一线治疗滤泡性淋巴瘤：皮下vs静脉

2017-08-15

heli0118 (审核中...)

前往app查看评论内容

#利妥昔#

Arthritis Rheumatol：利妥昔单抗治疗原发性干燥综合征患者疲乏和口干令人失望

2018-07-11

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

JAMA Dermat：利妥昔单抗治疗顽固性疱疹样皮炎

2017-02-06

科室
- - 订阅+
  - 更多科室
工具
服务